Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Aug 25:2:6715.
doi: 10.4076/1757-1626-2-6715.

Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report

Kevin C Cronin  1 , Gabrielle C Colleran, Andrew Smyth, Diarmuid D Houlihan, Thomas A O'Gorman
Affiliations
Case Reports

Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report

Kevin C Cronin et al. Cases J. .

Abstract

A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral mesalazine due to failure to improve.He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His condition settled with conservative management and IV antibiotics.Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2 doses he developed rigors, pyrexia, tachycardia and vomiting.Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine has not been re-introduced.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. 2004;4(2):86–91. - PubMed
    1. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–539. doi: 10.1136/gut.51.4.536. - DOI - PMC - PubMed
    1. Raithel M, Baenkler HW, Naegel A, Buchwald F, Schultis HW, Backhaus B, Kimpel S, Koch H, Mach K, Hahn EG, Konturek PC. Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol. 2005;56(5):89–102. - PubMed
    1. Gonzalo MA, Alcalde MM, García JM, Alvarado MI, Fernández L. Desensitization after fever induced by mesalazine. Allergy. 1999;54(11):1224–1225. doi: 10.1034/j.1398-9995.1999.00298.x. - DOI - PubMed
    1. Halfvarson J, Jarnerot G. Treatment of choice for acute severe steroid-refractory ulcerative colitis is remicade. Inflamm Bowel Dis. 2009;15(1):143–145. doi: 10.1002/ibd.20782. - DOI - PubMed

Publication types

LinkOut - more resources